ABSTRACT
Nonmuscle-invasive TCC (Ta, T1) is another clinical situation in which recurrence and progression rates may be modified by intravesical BCG. The risk of recurrence after initial resection is 80% in patients with Ta or T1 tumors that were followed for a minimum of 20 years.13 A subset of patients within this group are at highest risk, namely those with large, multiple, poorly differentiated tumors or concurrent CIS.
